Hepatic artery infusion of chemotherapy following resection of liver metastases

Conclusions

HAI chemotherapy, when added to systemic chemotherapy following resection of liver metastases, significantly reduces the risk of hepatic progression of colorectal cancer and results in a greater proportion of patients surviving 2 years after resection. However, median overall survival and median overall progression-free survival are not significantly improved by the addition of HAI chemotherapy. The addition of HAI chemotherapy produces greater toxicity and a higher rate of hospitalization for management of toxicity. Better systemic chemotherapy is still sorely needed to optimize the management of patients with metastatic colorectal cancer.